Alnylam Comments on FDA Approv –

Alnylam+Pharmaceuticals%2C+Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration’s (FDA) approval of Leqvio® (inclisiran), the fourth small interfering RNA (siRNA) therapy (or RNAi therapeutic) approved in the U.S., and the first and only to lower low-density lipoprotein cholesterol (also known as “bad cholesterol” or LDL-C). Leqvio is indicated in the U.S. as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of LDL-C. Alnylam scientists discovered inclisiran and published the first clinical data. Alnylam also supported early clinical development. As of January 2020, Novartis has obtained global rights to develop, manufacture and commercialize inclisiran under a license and collaboration agreement. Novartis AG continues to develop inclisiran and commercialize Leqvio worldwide, with Alnylam eligible to receive tiered royalties between 10 and 20 percent on global sales.

Leqvio is the fourth Alnylam-discovered medicine using its RNAi therapeutic platform to be approved to date. The Leqvio approval marks the first U.S. approval of an RNAi therapeutic indicated to treat a major risk factor for a highly prevalent disease. Alnylam launched its first RNAi therapeutic in 2018 with the FDA approval of ONPATTRO® (patisiran) for treatment of the polyneuropathy caused by hATTR amyloidosis, a progressive and life-threatening, rare, genetic disease. Leqvio was approved to lower LDL cholesterol and has the potential to benefit millions of people with ASCVD and also those with HeFH around the world.

“The approval of Leqvio, a potentially transformational medicine for lowering LDL-C is a historic event for Alnylam and its RNAi therapeutics platform. The demonstrated ability of Leqvio to lower LDL cholesterol up to 52% versus placebo on top of maximally tolerated statins with just two doses per year after an initial dose and another at three months represents a breakthrough that carries the potential to treat millions of people with ASCVD who are struggling to control elevated LDL cholesterol,” said John Maraganore, Ph.D., Chief Executive Officer of Alnylam. “More broadly, we believe the approval of Leqvio validates the future potential of RNAi therapeutics in large population diseases, and facilitates Alnylam’s advancement toward its bold Alnylam P5x25 strategy and goals. We are proud to share in the significance of this milestone with Novartis who made this approval a reality.”

History of Leqvio (inclisiran)

Inclisiran was discovered by Alnylam and, in collaboration with The Medicines Company, advanced into clinical development in 2014. Upon successful completion of Phase 1 clinical studies, the ORION clinical program was launched in 2015. The FDA approval was based on results from the comprehensive Phase III ORION-9, -10 and -11 clinical trials, where all of the 3,457 participants with ASCVD or HeFH had elevated LDL-C while being on a maximally tolerated dose of statin therapy. This comprehensive Phase 3 program represents the largest clinical program conducted to date for an investigational RNAi therapeutic program. Two complementary Phase 3 cardiovascular outcomes trials, ORION-4 and the Novartis initiated VICTORION-2-PREVENT are currently ongoing.

“We believe that the creation of Leqvio …….


Leave a Reply

Your email address will not be published. Required fields are marked *



[COLUMN] 4th COVID-19 shot? — – Asian Journal News

OMICRON is super-contagious and skyrocketing across the nation, while the virus continues to replicate and mutate mostly in the bodies of those more than 50 million unvaccinated people in the U.S. who are “carriers/transmitters” causing the current massive surges (almost a million last week) in COVID-19 infections, 70,000 hospitalizations, and about 1,300 deaths daily. Indeed, this is mostly the pandemic of the unvaccinated. Those with the booster must still be careful, since they still have a 5-10 percent chance of getting infected, especially with Omicron and future strains.

In spite of the more than 829,000 deaths in the U.S. from COVID-19, the government still refus…….


ZetaClear Reviews: Nail Fungus Topical Treatment Really Works or SCAM? – Inter Press Service

You could be scammed if you don’t order Zetaclear Nail Fungus online from the official website.

These products are often made in China, with low-quality ingredients and harmful chemicals.

All of us want to live a happy life without any problems. There are many issues that people come across in their lives. The most serious is the one that has a direct impact on your health. Many people have allergies. The infection can spread quickly and isn’t always predictable. ZetaClear It is important to protect such conditions from bacteria. One example is fungus infection in the nails of the legs and hands. It can be difficult to clean this area and it can cause the enti…….